Microsoft fixes 167 security flaws in April, second biggest Patch Tuesday ever
THE SO WHAT
167 vulnerabilities in a single Patch Tuesday — second only to October 2025 — is a reminder that your real risk surface is the patching lag, not the CVEs. If you’re rolling out AI or any new infra, pair it with a ruthless patch management discipline or you’re just widening the blast radius.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechIn vivo CAR-T race for autoimmune grows as two RNA startups enter the clinic
In vivo CAR-T for autoimmune moving into human trials shifts cell therapy from bespoke, ex vivo workflows to something that looks more like a repeatable drug platform. If you’re in healthcare delivery or biotech tooling, assume the bottleneck moves from lab capacity to in-clinic monitoring, data, and safety infrastructure over the next cycle.
Deep & Emerging Tech'We are currently being extorted' — crypto giant Kraken says it is facing extortion attack, here's what we know
A major exchange facing an alleged insider-linked extortion attempt is a reminder that your highest-risk attack surface is still internal access and incentives, not just perimeter defenses. If you’re holding customer assets or sensitive models, revisit insider threat monitoring and escalation paths this week, not after the ransom note arrives.
Deep & Emerging TechCould pressure to make money faster kill the next lifesaving pill?
Activist pressure is shortening drug-development time horizons—R&D portfolios are being optimized for near-term cash, not outlier cures. If you’re building tools for biotech, sell on derisking and capital efficiency for late-stage assets, not on enabling moonshot pipelines.
Deep & Emerging TechBiogen filing reveals Apellis deal details; Telix raises $600M
Biogen’s $5.6B Apellis buy and Telix’s $600M raise show public markets are rewarding de-risked, late-stage biology again—XBI’s risk appetite is back. For tools and infra vendors, the buyer with budget is the company in Phase 2/3, not the seed-stage platform play.